Codexis (CDXS) to Release Quarterly Earnings on Wednesday

Key Points

• Codexis is set to announce its Q2 2025 earnings on August 13, expecting a loss of ($0.17) per share and revenue of $14.18 million.
• The company recently reported a negative return on equity of 118.47% and a net margin of 149.47%, missing previous revenue estimates.
• Shares of Codexis are currently up 3.2%, with the stock trading at $2.93, and institutional investors hold about 78.54% of the company's stock.

Codexis (NASDAQ:CDXS - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $14.18 million for the quarter. Codexis has set its FY 2025 guidance at EPS.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative return on equity of 118.47% and a negative net margin of 149.47%. The business had revenue of $7.54 million for the quarter, compared to analyst estimates of $10.38 million. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Stock Up 3.2%

Shares of CDXS opened at $2.93 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 3.64 and a current ratio of 3.72. Codexis has a one year low of $1.90 and a one year high of $6.08. The stock has a market capitalization of $242.75 million, a price-to-earnings ratio of -2.96 and a beta of 2.54. The stock has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.91.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Codexis to a "sell" rating in a research report on Friday, May 16th.

Institutional Trading of Codexis

A hedge fund recently raised its stake in Codexis stock. Royal Bank of Canada raised its stake in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 24.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 437,126 shares of the biotechnology company's stock after buying an additional 87,044 shares during the quarter. Royal Bank of Canada owned approximately 0.53% of Codexis worth $1,176,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 78.54% of the company's stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.